glp-1 kidney protection Receptor Agonists in Diabetic Disease: From Clinical Outcomes to Mechanisms GLP-1 agonists in the treatment
Description
Nyberg J, Jacobsson C, Anderson MF, Eriksson PS
Editorial Advisory Board Member, Harvard Health Publishing Disclaimer: As a service to our readers, Harvard Health Publishing provides access to our library of archived content
muciniphila and bacteria that can produce SCFAs
A number of initiatives in addition to GLP-1 coverage limits contributed to Blue Crosss positive operating income, Guerriere said
doi:10.1080/17425255.2018.1488965 41
